BioBridge Global Introduces BBG Advanced Therapies: New Subsidiary to Support the Development of Cell and Gene Therapies

Jewish American Heritage Month: Recognizing a pioneer in blood science

Ludwik Hirszfeld survived the Holocaust and made multiple discoveries about blood

One of the pioneers of blood group science and blood transfusion was Ludwik Hirszfeld, a Polish physician, immunologist, and microbiologist born in 1884. Hirszfeld was Jewish and survived the Holocaust in Eastern Europe and even helped people through medicine in the Warsaw Ghetto. 

Hirszfeld is credited with helping discover and coin the different ABO blood types, finding out along with scientist Emil von Dungern that human blood types are inheritable, and discovering blood group frequency differences between populations with his wife, scientist Hanna Hirszfeld. He made fundamental discoveries and contributions in immunogenetics and immunohematology. 

Discoveries during the First World War

Through both world wars, Hirszfeld’s commitment to science and medicine helped many people to survive typhus and typhoid fever epidemics. He served as a Serbian Army doctor in World War I and made important scientific findings about strains of typhoid. His introduction of mass disinfection helped slow the spread of the epidemic. 

With his wife, he acquired blood samples from thousands of soldiers of different races and ethnicities during World War I and used the information they collected about blood types as a basis for theories that blood types are tied to different geographical locations and ethnicities that originated with one “pure blood type.” These false theories were later adopted and transformed into the basis for a “superior race” and eugenics in Nazi Germany. 

After the war, Hirszfeld helped create the National Institute of Hygiene in Warsaw and developed blood transfusion centers in Poland.  

Helping others during the Holocaust

During World War II, Hirszfeld was sent to the Warsaw Ghetto, where he helped organize secret medical courses and led the way in containing the typhus epidemic that plagued the ghetto. He designed a simple test to detect typhoid bacteria in urine and secretly vaccinated people against the disease. Hirszfeld taught more than 500 students about bacteriology and more, but only 50 of those students survived the war. 

He detailed the horrors of overcrowding, starvation, and non-existent healthcare in the ghetto in his book, “The Story of One Life.” He and Hanna escaped the ghetto in 1941.  

Continued blood science discoveries

Hirszfeld’s research continued after the war, with one of his greatest findings at that time being the theory of serological conflict between mother and fetus, which addresses hemolytic disease of the fetus and newborn that is caused by incompatibility of the Rh antigen. He introduced exchange transfusions, which saved nearly 200 children at the time.  

He co-authored 395 scientific papers in his lifetime, and more than half of them were about blood science and transfusion. 

To learn more about blood donation, visit SouthTexasBlood.org.

Source: Ludwik Hirszfeld: A pioneer of transfusion and immunology during the world wars and beyond – PMC (nih.gov) 

‘It’s a phenomenal time to be part of San Antonio.’ BBG leadership talks healthcare innovation at Invest: San Antonio

San Antonio and its surrounding areas are ripe for investment and opportunity, according to several city business leaders who presented at the Invest: San Antonio 2022-23 Leadership Summit.  

Among them were BioBridge Global’s Becky Cap, who spoke on the panel, “Twin Pillars: How healthcare and higher education are driving innovation and economic diversity across Greater San Antonio” at the summit on May 17.  

“What I’m seeing today in San Antonio is so exciting, and being at BioBridge Global, we’re able to touch so much of it,” said Cap, Senior Vice President, Business Development and Advanced Therapies. “It’s a phenomenal time to be a part of San Antonio.” 

As the South Texas population grows rapidly, Cap noted how BioBridge Global has continued to innovate to meet demand and invest in healthcare access through building new donor centers, expanding manufacturing capacity for advanced therapies development, engaging more blood donors than ever, and more.  

“On the therapeutic development side, we are in a rapidly growing and emerging market – highly innovative – so it’s all about the agility and collaboration and developing our capabilities and our workforce in collaboration with higher ed,” she said. 

Cap and her team have played a vital role in building relationships with higher education institutions for internships with BBG’s biomanufacturing subsidiary, GenCure. A continuing challenge is developing the healthcare workforce. 

“Right now, roughly 90% of therapies that go into clinical trials don’t get through,” she said. “So how can we make that a more efficient process and increase the therapeutic power of those options? 

“That’s where we get another tie into the educational programs targeted to computer science, development and to the hospitals.” 

The panel also included Joe Fisher, Hallmark University president and CEO; Tarra Washington, CEO of Kindred Hospital San Antonio Medical Center; and Robert Garza, president of Palo Alto College. The panel was moderated by Dr. Shreekanth Mandayam, vice president for research at Texas State University. 

Capital Analytics, an integrated media platform, hosted the event and launched its annual business guide as a review of issues facing the South Texas economy, with insights from industry leaders across the region, including BioBridge Global CEO Martin Landon, who is featured in a Q+A. Other panels at the summit focused on real estate, economic development, and infrastructure growth.